Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Surovatamig - AstraZeneca

Next Previous
Drug Profile

Surovatamig - AstraZeneca

Alternative Names: AZD-0486; CD19 x CD3 T-BsAb - TeneoBio; TNB-486

Latest Information Update: 15 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TeneoTwo
  • Developer AstraZeneca; TeneoBio; TeneoTwo
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Follicular lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 10 Oct 2025 AstraZeneca plans a phase III SOUNDTRACK-D2 trial for B cell lymphoma (In the elderly, First-line therapy) in Australia, Belgium, Brazil, Canada, China, Hong Kong, Japan, South Korea in November 2025 (NCT07215585)
  • 01 Oct 2025 AstraZeneca plans a phase I ASSURO trial in Rheumatoid arthritis or Systemic lupus erythematosus (Treatment-resistant) in November 2025 (SC) (NCT07201558)
  • 30 May 2025 Updated adverse events and efficacy data from a phase I trial in Non-Hodgkin's lymphoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top